Indonesia Urges Greater Transparency in Cross-Border Copyright Royalty Governance Before 35 Countries 
SaunaKits.com Opens Its Upstate South Carolina Showroom, Bringing Hands-On Sauna Shopping to the Southeast 
Encore Construction Shares Guidance to Help Homeowners Avoid Costly Water Damage Insurance Claim Mistakes Thomas P. Slavin, M.D., Named Chief Medical Officer for Myriad Genetics
Dr. Slavin Brings Deep Clinical, Academic and Industry Experience to New Role SALT LAKE CITY,…
Bioventus to Release Second Quarter of Fiscal Year 2021 Financial Results on August 10, 2021
DURHAM, N.C., June 16, 2021 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the…
Satsuma Pharmaceuticals Announces Positive Pharmacokinetic, Tolerability and Safety Results From Phase 1 Trial of STS101 at Multiple Dose Strengths
– All three dose strengths of STS101, administered with improved 2nd-generation nasal delivery device were…
Tarsus Pharmaceuticals, Inc. Initiates Phase 1 Callisto Trial of TP-05, a Novel, Oral, Non-Vaccine Therapeutic for the Prevention of Lyme Disease
More than 30 million Americans at risk for Lyme disease exposure, which can result in…
Collegium Announces Publication of Real-World Data in Journal of Pain Research
STOUGHTON, Mass., June 16, 2021 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical…
Evelo Biosciences Announces Grant of Inducement Award
CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical…
Novan Announces Proposed Public Offering of Common Stock
DURHAM, N.C., June 16, 2021 (GLOBE NEWSWIRE) — Novan, Inc. (the “Company” or “Novan”) (NASDAQ:…
On substantial participation
JSC Olainfarm has received announcements on substantial participation from Anna Emīlija Maligina, SIA “OLMAFARM” and SIA…
Better Choice Announces Offering of Common Stock Concurrent With Uplisting to the NYSE American Stock Exchange
NEW YORK, June 16, 2021 (GLOBE NEWSWIRE) — Better Choice Company (OTCQX: BTTR) (“Better Choice”),…
Kane Biotech launches 2021 business update series
Premiere episode “The Fundamentals” available now WINNIPEG, Manitoba, June 16, 2021 (GLOBE NEWSWIRE) — Kane…
LifeSci Acquisition II Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination
NEW YORK, June 16, 2021 (GLOBE NEWSWIRE) — LifeSci Acquisition II Corp. (NASDAQ: LSAQ), a…
Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Present on Advances Using Camelina Platform to Produce PHA Bioplastic at 2021 Synthetic Biology: Engineering, Evolution and Design Virtual Conference
WOBURN, Mass., June 16, 2021 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience…
Mustang Bio to Present at the Raymond James Human Health Innovation Conference
WORCESTER, Mass., June 16, 2021 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a…
Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel
SAN DIEGO, June 16, 2021 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical…
Zealand Pharma to Present Data on Glucagon Analog, Dasiglucagon, at the 81st Annual American Diabetes Association Scientific Sessions
Company announcement – No. 39/2021 Zealand Pharma to Present Data on Glucagon Analog, Dasiglucagon, at…
KBP Biosciences Announces A Greater Than 10 mm Hg Systolic Blood Pressure Reduction in The BLOCK-CKD Phase 2b Study of KBP-5074 in Advanced Chronic Kidney Disease Patients with Uncontrolled Hypertension as Published in Hypertension
KBP-5074, a highly-selective non-steroidal mineralocorticoid receptor antagonist, lowered clinic systolic blood pressure (SBP) by 10.2…
VistaGen Therapeutics Set to Join the Russell 2000® Index
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) — VistaGen Therapeutics, Inc. (NASDAQ: VTGN),…
Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) announced activation of…
Neurona Therapeutics Presents Clinical Development Plan for Lead Cell Therapy Program at the 16th Conference on Antiepileptic Drug and Device Trials (AEDD TRIALS XVI)
Supporting data in preclinical model of drug-resistant epilepsy demonstrate seizure-freedom in 70% of the NRTX-1001…
Selecta Biosciences to Participate at the Raymond James Human Health Innovation Conference
WATERTOWN, Mass., June 16, 2021 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology…